<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575913</url>
  </required_header>
  <id_info>
    <org_study_id>L_8935</org_study_id>
    <nct_id>NCT00575913</nct_id>
  </id_info>
  <brief_title>Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study</brief_title>
  <acronym>ALEX-XL</acronym>
  <official_title>ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To assess, under daily practice conditions, the safety profile and the efficacy of a new
      formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary
      tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvements in urinary symptoms and quality of life index</measure>
    <time_frame>During all the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in sexual function</measure>
    <time_frame>During all the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in maximum flow rate (determined by uroflowmetry)</measure>
    <time_frame>During all the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of spontaneously reported adverse events</measure>
    <time_frame>At each visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">118</enrollment>
  <condition>Prostatic Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <description>Alfuzosin 10 mg One tablet per day after evening meal</description>
    <other_name>(Xatral XL)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory patients suffering from lower urinary tract symptoms suggestive of BPH.

        Exclusion Criteria:

          -  Patients requiring BPH surgery immediately or within the 12 following months:

               -  Acute renal obstruction

               -  Chronic renal obstruction

               -  Chronic renal failure from BPH

               -  Bladder stone

               -  Recurrent urinary tract infection

               -  Other bladder pathology such as cancer of the bladder, bladder bidiverticulum
                  (big size)

               -  Hematuria from BPH

          -  Patients whose urinary symptoms are satisfactorily controlled on other BPH medication
             ( alpha-blockers or 5 alpha-reductase)

          -  Patients previously not improved by an alpha1-blocker treatment

          -  Known hypersensitivity to alfuzosin

          -  History of postural hypotension or syncope

          -  Combination with other alpha1-blockers

          -  Hepatic enzyme (SGOT or/and SGPT ) &gt; 1.5 Upper Normal Limit

          -  Unstable angina pectoris

          -  Severe concomitant condition threatening life.

          -  Patients who had failed treatment with finasteride (Proscar)

          -  Patients with neuropathic bladder.

          -  Patients with history of previous surgery for BPH

          -  Patients with high risk for prostate cancer based on the clinical judgement of the
             investigator

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paibulsirijit Sompob</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>April 8, 2008</last_update_submitted>
  <last_update_submitted_qc>April 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

